TheStreet Upgrades VEON (NASDAQ:VEON) to C-

Share on StockTwits

VEON (NASDAQ:VEON) was upgraded by research analysts at TheStreet from a “d+” rating to a “c-” rating in a research report issued to clients and investors on Thursday, TheStreetRatingsTable reports.

Several other brokerages also recently commented on VEON. BidaskClub downgraded shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday. Zacks Investment Research upgraded shares of SCHNEIDER ELEC /ADR from a “hold” rating to a “buy” rating and set a $20.00 price objective on the stock in a research report on Friday, July 5th. UBS Group downgraded shares of JinkoSolar from a “buy” rating to a “neutral” rating and raised their price objective for the company from $22.00 to $25.00 in a research report on Monday, June 17th. Bank of America restated a “buy” rating and set a $43.00 price objective (up from $36.00) on shares of The Medicines in a research report on Tuesday. Finally, ValuEngine downgraded shares of Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, May 28th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $3.19.

VEON traded down $0.03 during trading on Thursday, hitting $3.17. The company’s stock had a trading volume of 3,871,004 shares, compared to its average volume of 8,837,672. VEON has a one year low of $2.07 and a one year high of $3.28. The stock has a market cap of $5.62 billion, a price-to-earnings ratio of -13.78 and a beta of 1.81. The stock has a 50 day moving average price of $2.61.

VEON (NASDAQ:VEON) last released its quarterly earnings results on Thursday, May 2nd. The Wireless communications provider reported $0.08 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.06 by $0.02. The business had revenue of $2.12 billion for the quarter. VEON had a net margin of 10.00% and a negative return on equity of 17.37%. As a group, analysts forecast that VEON will post 0.39 earnings per share for the current year.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Comerica Bank grew its position in VEON by 4.0% during the 4th quarter. Comerica Bank now owns 105,471 shares of the Wireless communications provider’s stock worth $262,000 after purchasing an additional 4,101 shares during the last quarter. New York State Common Retirement Fund acquired a new position in shares of VEON in the 4th quarter valued at $137,000. Citigroup Inc. raised its position in VEON by 6,555.8% during the fourth quarter. Citigroup Inc. now owns 46,990 shares of the Wireless communications provider’s stock worth $109,000 after acquiring an additional 46,284 shares during the period. Connor Clark & Lunn Investment Management Ltd. acquired a new position in VEON during the fourth quarter worth $63,000. Finally, Hsbc Holdings PLC raised its position in VEON by 15.1% during the fourth quarter. Hsbc Holdings PLC now owns 1,481,318 shares of the Wireless communications provider’s stock worth $3,466,000 after acquiring an additional 194,554 shares during the period. 16.22% of the stock is owned by institutional investors.

About VEON

VEON Ltd., through its subsidiaries, provides mobile and fixed-line telecommunications services. It offers voice and data telecommunication services through a range of mobile and fixed-line technologies. The company provides value added services, including short messages, multimedia messages, caller number identification, call waiting, data transmission, mobile internet, downloadable content, mobile finance services, machine-to-machine, and other services; national and international roaming services; wireless Internet access and mobile financial services; and mobile bundles and call completion services.

Recommended Story: Earnings Reports

Analyst Recommendations for VEON (NASDAQ:VEON)

Receive News & Ratings for VEON Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VEON and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.